Moderna reported second quarter 2026 financial results with total revenue of $145 million and a GAAP net loss of $(0.8) billion, or $(1.97) per share. The company improved its full-year 2026 operating expense outlook by approximately $0.2 billion and raised its expected year-end cash balance to $4.7–$5.2 billion. Pipeline updates included a unanimous VRBPAC recommendation for the seasonal influenza vaccine mFLUSIVA ahead of an August 5 PDUFA date, while the norovirus candidate mRNA-1403 failed to meet early success criteria in Phase 3. Moderna also appointed Ester Banque as Chief Commercial Officer and Michael McDonnell to its Board of Directors. The company operates in the biotechnology industry, specializing in mRNA-based vaccines and therapeutics.

Moderna, Inc. appointed Michael McDonnell to its Board of Directors as a Class II director, effective July 8, 2026. Mr. McDonnell, a former CFO of Biogen Inc. and IQVIA Holdings Inc., will also serve on the Audit Committee. Concurrently, David Rubenstein transitioned from the Audit Committee to the Nominating and Corporate Governance Committee. Moderna, Inc. is a biotechnology company that develops mRNA technology for vaccines and therapeutics.